Loading…
Employees: 2,700
Size Myriad Genetics (MYGN) is a United States Health Care company (Medical Specialties) with a market value of $566M, the 2609th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.92 on 6 Nov 2026.
Performance Over six months the shares gained 38.0%, against -13.2% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +9.3%); the operating margin is -11.2% (peer median 6.3%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 4.5× (cheapest of 18).
Capital Return on invested capital runs 28.5 points below its cost of capital (10.9% WACC).
Short interest Short interest is 9.7% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $807M | $824M | $838M | $753M | $678M |
| Revenue growth | — | -2% | +11% | +11% | — |
| Gross profit | $525M | $577M | $585M | $474M | $435M |
| EBITDA | -$41.4M | -$13.6M | -$26.0M | -$71.4M | -$53.9M |
| Net income | -$113M | -$366M | -$127M | -$263M | -$112M |
| Free cash flow | -$7.30M | -$13.8M | -$27.7M | -$174M | -$152M |
| Capital expenditure | $21.9M | $27.4M | $29.7M | $73.3M | $45.3M |
| Total debt | $210M | $210M | $140M | $152M | $145M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MYGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +41.0% | -3.3% | 2nd highest of 20 |
| 6-month return | +38.0% | -13.2% | 2nd highest of 20 |
| Distance from 52-week high | -26.8% | -39.9% | 6th highest of 20 |
| Revenue growth (TTM) | -3.2% | +9.3% | 6th lowest of 20 |
| Operating margin | -11.2% | 6.3% | 5th lowest of 20 |
| EV / Sales | 0.8× | 4.5× | cheapest of 18 |
| ROIC minus cost of capital | -28.5 pp | -1.3 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 6.8× | -1.8% | +14.5% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 1.7× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 5.6× | n/a | n/a |